within Pharmacolibrary.Drugs.ATC.R;

model R03DX09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.716666666666667e-06,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0036,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0027,
    k12             = 0.0607,
    k21             = 0.0607
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03DX09</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mepolizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), used as an add-on maintenance treatment for severe eosinophilic asthma and hypereosinophilic syndrome. It is approved by major regulatory agencies including FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with severe eosinophilic asthma; data based on population pharmacokinetic analysis from clinical trials.</p><h4>References</h4><ol><li><p>Ortega, H, et al., &amp; Cozens, S (2014). Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. <i>Clinical pharmacology in drug development</i> 3(1) 57–62. DOI:<a href=\"https://doi.org/10.1002/cpdd.60\">10.1002/cpdd.60</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27128231/\">https://pubmed.ncbi.nlm.nih.gov/27128231</a></p></li><li><p>Smith, DA, et al., &amp; Beerahee, M (2011). Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. <i>Clinical pharmacokinetics</i> 50(4) 215–227. DOI:<a href=\"https://doi.org/10.2165/11584340-000000000-00000\">10.2165/11584340-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21348536/\">https://pubmed.ncbi.nlm.nih.gov/21348536</a></p></li><li><p>Gupta, A, et al., &amp; Yancey, SW (2019). Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. <i>Pediatric pulmonology</i> 54(12) 1957–1967. DOI:<a href=\"https://doi.org/10.1002/ppul.24508\">10.1002/ppul.24508</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31502421/\">https://pubmed.ncbi.nlm.nih.gov/31502421</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03DX09;
